Clinical Trial: To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364422) titled 'To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer' on Jan. 11.

Brief Summary: This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer

Study Start Date: Feb. 27

Study Type: INTERVENTIONAL

Condition: Gastric Cancer (GC)

Intervention: DRUG: JPI-547

The dose levels will be escalated following a 3+3 dose escalation scheme.

DRUG: Irinotecan (drug)

The dose levels will be escalated following a 3+3 dose escalation scheme.

Recruitmen...